

<b>Application Number</b>	10/568,745
<b>Filing Date</b>	02-21-06
<b>First Named Inventor</b>	Mitsuko Ideno
<b>Art Unit</b>	1644
<b>Examiner Name</b>	Z. SKELDING
<b>Attorney Docket Number</b>	1422-0709PUS1

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **2** of **5****Complete if Known**

Application Number	10/568,745
Filing Date	02-21-06
First Named Inventor	Mitsuko Ideno
Group Art Unit	1644
Examiner Name	Z. SKELDING
Attorney Docket Number	1422-0709PUS1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initial *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T 2
	3	"Animal Cell Culture: A Practical Approach", Edited by R.I. Freshney, IRL Press, Oxford, Washington, D.C., 1986, pp. 26-41	<input type="checkbox"/>
	4	"Animal Cell Culture: A Practical Approach", Edited by R.I. Freshney, Moscow, 1989, pp. 44, 53, 77	<input checked="" type="checkbox"/>
	5	Advisory Action for US Application No. 10/509,055, dated June 9, 2009	<input type="checkbox"/>
	6	Advisory Action for US Application No. 11/790,025, dated April 2, 2010	<input type="checkbox"/>
	7	AZUMA et al., "Functional Expression of B7/BB1 on Activated T Lymphocytes", J. Exp. Med., Vol. 177, March 1993, pp. 845-850	<input type="checkbox"/>
	8	BLUE et al. "Enhancement of CD2-Mediated T Cell Activation by the Interaction of VLA-4 with Fibronectin", Cellular Immunology, Vol. 138, 1991, pp. 238-244	<input type="checkbox"/>
	9	Board of Patent Appeals and Interferences Decision - Examiner Reversed for US Application No. 10/344,534, dated May 28, 2010	<input type="checkbox"/>
	10	Chinese Office Action for Application No. 200480024172.7, dated January 15, 2010	<input type="checkbox"/>
	11	Communication from USPTO regarding Information Disclosure Statement for US Application No. 10/344,534, dated July 23, 2009	<input type="checkbox"/>
	12	Examiner Interview Summary for US Application No. 10/344,534, dated February 5, 2008	<input type="checkbox"/>
	13	Examiner Interview Summary for US Application No. 10/344,534, dated June 4, 2008	<input type="checkbox"/>

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **3** of **5****Complete if Known**

Application Number	10/568,745
Filing Date	02-21-06
First Named Inventor	Mitsuko Ideno
Group Art Unit	1644
Examiner Name	Z. SKELDING
Attorney Docket Number	1422-0709PUS1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initial *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T 2
	14	Examiner Interview Summary for US Application No. 10/486,512, dated August 2, 2007	<input type="checkbox"/>
	15	Extended European Search Report, Application No. EP 09004189.8-1222/2070542, December 8, 2009, 6 pages	<input type="checkbox"/>
	16	FUNARO et al., "Stimulation of T Cells via CD44 Requires Leukocyte-Function-Associated Antigen Interactions and Interleukin-2 Production", Human Immunology, Vol. 40, 1994, pps. 267-278	<input type="checkbox"/>
	17	JOHNSON et al., "Expression and Function of Insulin-Like Growth Factor Receptors on Anti-CD3-Activated Human T Lymphocytes", Journal of Immunology, Vol. 148, No. 1, January 1, 1992, pp. 63-71	<input type="checkbox"/>
	18	JUNG et al., "Induction of Cytotoxicity in Human Peripheral Blood Mononuclear Cells by Monoclonal Antibody OKT3", Journal of Immunology, Vol. 139, No. 2, July 15, 1987, pp. 639-644	<input type="checkbox"/>
	19	KANTO et al., "Neutralization of Transforming Growth Factor $\beta$ -1 Augments Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Induction In Vitro", Journal of Clinical Immunology, Vol. 17, No. 6, 1997, pp. 462-471	<input type="checkbox"/>
	20	KATZMAN et al., "Fibronectin and Cellular Cytotoxicity: Evidence Against a Role for Fibronectin in Natural Killer Activity", J. Lab. Clin. Med., Vol. 110, No. 1, July 1987, pp. 75-82	<input type="checkbox"/>
	21	LUCIVERO et al., "Functional Characteristics of Cord Blood T Lymphocytes After Lectin and Anti-CD3 Stimulation", Int. J. Clin. Lab. Res., Vol. 26, 1996, pp. 255-261	<input type="checkbox"/>
	22	NERI et al., "Calcein-Acetyloxymethyl Cytotoxicity Assay: Standardization of a Method Allowing Additional Analyses on Recovered Effector Cells and Supernatants", Clin. and Diag. Lab. Immunol., Vol. 8, No. 6, November 2001, pp. 1131-1135	<input type="checkbox"/>
	23	Partial European Search Report, Application No. 09004189.8-1222/2070542, August 3, 2009, 3 pages	<input type="checkbox"/>
	24	PAWELEC et al., "Extrathymic T Cell Differentiation in Vitro From Human CD34+ Stem Cells", Journal of Leukocyte Biology, Vol. 64, December 1998, pp. 733-739	<input type="checkbox"/>

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 5

**Complete if Known**

Application Number	10/568,745
Filing Date	02-21-06
First Named Inventor	Mitsuko Ideno
Group Art Unit	1644
Examiner Name	Z. SKELDING
Attorney Docket Number	1422-0709PUS1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initial *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T 2
	25	STOHL et al., "Generation of Cytolytic Activity with Anti-CD3 Monoclonal Antibodies Involves Both IL-2-Independent and -Dependent Components", J. Immunol., Vol. 144, No. 10, May 15, 1990, pp. 3718-3725	<input type="checkbox"/>
	26	TAMURA et al., "Expression and Function of c-Met, a Receptor for Hepatocyte Growth Factor, During T-Cell Development", Scandinavian Journal of Immunology, 1998, Vol. 47, pp. 296-301	<input type="checkbox"/>
	27	US Office Action for Application No. 10/486,512, dated April 19, 2010	<input type="checkbox"/>
	28	US Office Action for Application No. 10/486,512, dated June 23, 2009	<input type="checkbox"/>
	29	US Office Action for Application No. 10/486,512, dated September 30, 2009	<input type="checkbox"/>
	30	US Office Action for Application No. 10/509,055, dated April 14, 2010	<input type="checkbox"/>
	31	US Office Action for Application No. 10/509,055, dated September 3, 2009	<input type="checkbox"/>
	32	US Office Action for Application No. 11/790,025, dated December 18, 2009	<input type="checkbox"/>
	33	US Office Action for Application No. 11/790,025, dated May 7, 2009	<input type="checkbox"/>
	34	US Office Action for Application No. 11/831,423, dated March 18, 2010	<input type="checkbox"/>
	35	US Office Action for Application No. 11/831,423, dated May 27, 2009	<input type="checkbox"/>

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<b>Application Number</b>	10/568,745
<b>Filing Date</b>	02-21-06
<b>First Named Inventor</b>	Mitsuko Ideno
<b>Group Art Unit</b>	1644
<b>Examiner Name</b>	Z. SKELDING
<b>Attorney Docket Number</b>	1422-0709PIS1

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.